並列摘要
Both transvaginal ultrasonography and the serum biomarker CA125 have been used to screen for early ovarian cancer. Studies to date, however, have not demonstrated a clear effect of screening with transvaginal ultrasonography or CA125 on mortality from ovarian cancer. The prevalence of ovarian cancer in the normal postmenopausal population is about 1 in 2500. The low prevalence of the disease is the enemy of any reliable screening test for ovarian cancer. However, flank pain, abdominal bloating and pain, loss of appetite and fullness, and a variety of other abdominal, gastrointestinalm and urinary tract symptoms were recorded in significantly more women who were diagnosed with ovarian cancer cancer than in the control subjects. Therefore, there were to recommend evaluation of these signs and symptoms of ovarian cancer.